Ido Didi Fabian, Associate Professor at London School of Hygiene and Tropical Medicine, U. of London, shared on LinkedIn:
“I’m delighted to share the publication of the first paper from the Global Retinoblastoma Study 2024 in the British Journal of Ophthalmology: Global retinoblastoma service availability in 2024 and equity trends since 2017.
This study examines the worldwide availability of diagnostic and treatment services for retinoblastoma and how global equity has evolved since 2017.
This publication reflects the remarkable collaboration of hundreds of colleagues from around the world. My sincere thanks to every collaborator who contributed to this truly global effort and special thanks to Mattan Arazi for his invaluable contribution to this work .
We look forward to sharing many more findings from the 2024 cohort in the coming months.
Figure legend: Concentration curves for the proportional availability of retinoblastoma services by modality and year, ranked by GDP per capita: (a-b) diagnostic services, (c-d) chemotherapy, and (e–f) focal therapies in 2017 and 2024.”
Other articles about Retinoblastoma on OncoDaily.